{
  "directed": true,
  "graph": {
    "annotation_list": {
      "Assay": [
        "zymographic assay"
      ],
      "Concentration": [
        "1 μM",
        "10 μM"
      ],
      "Custom_CellLine": [
        "Vero E6 cell"
      ],
      "Custom_Disease": [
        "COVID-19"
      ],
      "PublicationStatus": [
        "Preprint"
      ],
      "PublicationType": [
        "Research"
      ],
      "Section": [
        "Results"
      ]
    },
    "annotation_pattern": {},
    "annotation_url": {
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20190128.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20190128.belanno",
      "Species": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Abish K",
      "contact": "abish@causalitybiomodels.com",
      "copyright": "Copyright © 2020 Fraunhofer Institute SCAI, All rights reserved",
      "description": "COVID Knowledge Curation project",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "name": "Rodrigues_et.al_2020.bel",
      "version": "2.0.0"
    },
    "namespace_pattern": {},
    "namespace_url": {
      "CHEBI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns",
      "COVID": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-covid19/ncbi-covid19-20200326.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns",
      "GO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns",
      "HGNC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns",
      "MESH": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns",
      "TAX": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
    },
    "path": "Rodrigues_et.al_2020.bel",
    "pybel_version": "0.14.6"
  },
  "links": [
    {
      "annotations": {
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "The more spontaneous binding of ATV, suggested by its lower energy score, may be related to its projected ability to form hydrogens bonds with the amino acid residues Asn142, His164, and Glu166 in Mpro, whereas the binding of LPV depends on hydrophobic interactions (Figure 2).",
      "key": "49ba9484dcfc94e9a4e61ff84ec80842",
      "line": 50,
      "relation": "association",
      "source": 7,
      "target": 5
    },
    {
      "annotations": {
        "Assay": {
          "zymographic assay": true
        },
        "Concentration": {
          "10 μM": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "In the infected cells, a region of activity was observed between 31 and 38 kDa that was not present in the mock fraction. This zone of molecular weight is consistent with expected size of SARS-CoV-2 Mpro as was the inhibition of activity in this region by exposure of the gels to 10 μM of ATV, which did not affect the cellular cysteine proteinase at 70 kDa (Figure 5, lanes ATV).",
      "key": "1925bc7c2a7d857439c0e20b06f63110",
      "line": 56,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 7,
      "target": 11
    },
    {
      "key": "683e87a3239ce4344e2bb3aa96319591",
      "relation": "partOf",
      "source": 0,
      "target": 7
    },
    {
      "annotations": {
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone, or in combination with RTV, inhibited infectious virus production and SARS-CoV RNA levels in Vero cells (Figure 6A and B, respectively).",
      "key": "4087f5cbd88677b3ebb52d8091641bef",
      "line": 69,
      "relation": "decreases",
      "source": 0,
      "target": 4
    },
    {
      "key": "1d88b34ab529e285e845a9bf0e967f62",
      "relation": "partOf",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "Concentration": {
          "1 μM": true
        },
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Moreover, we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant, which ranged from 20- to 60-fold depending on the cell donor (Figure 7C, open circles in nil-treated cells). The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 µM, ATV/RTV at both 1 and 10 µM and CQ at 10 µM (Figure 7C).",
      "key": "1993c5edb62caa4888f767ea0a729783",
      "line": 101,
      "relation": "decreases",
      "source": 0,
      "target": 12
    },
    {
      "key": "82102b8ab25b49890bf529d497cca814",
      "relation": "partOf",
      "source": 11,
      "target": 7
    },
    {
      "key": "010e33e5052eb7087922bf0a65e23c70",
      "relation": "partOf",
      "source": 11,
      "target": 8
    },
    {
      "key": "84a9f95a7d3b16f705d7150136b890fd",
      "relation": "hasVariant",
      "source": 10,
      "target": 11
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "The more spontaneous binding of ATV, suggested by its lower energy score, may be related to its projected ability to form hydrogens bonds with the amino acid residues Asn142, His164, and Glu166 in Mpro, whereas the binding of LPV depends on hydrophobic interactions (Figure 2).",
      "key": "1ec88344382757d138aa6dc4f13a1453",
      "line": 50,
      "relation": "association",
      "source": 5,
      "target": 7
    },
    {
      "annotations": {
        "Assay": {
          "zymographic assay": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Further confirmation of the presence and activity of SARS-CoV-2 Mpro in fractions from infected cells was obtained by treatment with RTV, which inhibited activity in the molecular range of 31-38 kDa without a change in the 70 kDa region (Figure 5, lanes RTV).",
      "key": "88f234c463788eb5d1c8ef67177a2b54",
      "line": 63,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 8,
      "target": 11
    },
    {
      "key": "5e45da475878ffddcba9a1d87780c69a",
      "relation": "partOf",
      "source": 2,
      "target": 8
    },
    {
      "key": "7d1badab9d783478fd3e08a0e675c4ff",
      "relation": "partOf",
      "source": 2,
      "target": 9
    },
    {
      "annotations": {
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone, or in combination with RTV, inhibited infectious virus production and SARS-CoV RNA levels in Vero cells (Figure 6A and B, respectively).",
      "key": "013598dae3128b644df9dfe7d8d368f9",
      "line": 71,
      "relation": "decreases",
      "source": 2,
      "target": 3
    },
    {
      "annotations": {
        "CellLine": {
          "A549 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 (Figure 6C) compared to Vero cells (Figure 6B). ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types (Figure 6B and C).",
      "key": "42e770208a7c6644a1d4d15d0eb8a682",
      "line": 79,
      "relation": "decreases",
      "source": 2,
      "target": 6
    },
    {
      "annotations": {
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone, or in combination with RTV, inhibited infectious virus production and SARS-CoV RNA levels in Vero cells (Figure 6A and B, respectively).",
      "key": "bf6bf09c452b3eafa0a188165c51a532",
      "line": 73,
      "relation": "association",
      "source": 4,
      "target": 3
    },
    {
      "annotations": {
        "CellLine": {
          "A549 cell": true
        },
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 (Figure 6C) compared to Vero cells (Figure 6B). ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types (Figure 6B and C).",
      "key": "8f2a832d396341c748b9d1c88f2e00b9",
      "line": 83,
      "relation": "association",
      "source": 4,
      "target": 6
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Another biomarker of uncontrolled pro-inflammatory cytokine response, TNF-α, was up-regulated 40-fold during virus infection (Figure 7D). Only the combination of ATV/RTV could significantly prevent the induction of TNF-α release (Figure 7D).",
      "key": "f3057666c23215388555796fef57efaa",
      "line": 110,
      "relation": "positiveCorrelation",
      "source": 4,
      "target": 14
    },
    {
      "annotations": {
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone, or in combination with RTV, inhibited infectious virus production and SARS-CoV RNA levels in Vero cells (Figure 6A and B, respectively).",
      "key": "5efe39bad81d8aeb889df7970971bcfe",
      "line": 70,
      "relation": "decreases",
      "source": 9,
      "target": 4
    },
    {
      "annotations": {
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone, or in combination with RTV, inhibited infectious virus production and SARS-CoV RNA levels in Vero cells (Figure 6A and B, respectively).",
      "key": "b6289cdd47d962020003b05f0cb95439",
      "line": 72,
      "relation": "decreases",
      "source": 9,
      "target": 3
    },
    {
      "annotations": {
        "CellLine": {
          "A549 cell": true
        },
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 (Figure 6C) compared to Vero cells (Figure 6B). ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types (Figure 6B and C).",
      "key": "e938acfe0aa8cff981067c6a75ae8171",
      "line": 81,
      "relation": "decreases",
      "source": 9,
      "target": 6
    },
    {
      "annotations": {
        "Cell": {
          "monocyte": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV/RTV and CQ were similarly efficient to inhibit viral replication in the human monocytes (Figure 7A).",
      "key": "1035fffc6fc773411caec753626961e5",
      "line": 91,
      "relation": "decreases",
      "source": 9,
      "target": 6
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Moreover, we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant, which ranged from 20- to 60-fold depending on the cell donor (Figure 7C, open circles in nil-treated cells). The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 µM, ATV/RTV at both 1 and 10 µM and CQ at 10 µM (Figure 7C).",
      "key": "cf5c73b8589bc5a30ff1ba18d5f2341e",
      "line": 106,
      "relation": "decreases",
      "source": 9,
      "target": 12
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Another biomarker of uncontrolled pro-inflammatory cytokine response, TNF-α, was up-regulated 40-fold during virus infection (Figure 7D). Only the combination of ATV/RTV could significantly prevent the induction of TNF-α release (Figure 7D).",
      "key": "6d54f634521969ce9a142212bbe69798",
      "line": 112,
      "relation": "decreases",
      "source": 9,
      "target": 13
    },
    {
      "annotations": {
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone, or in combination with RTV, inhibited infectious virus production and SARS-CoV RNA levels in Vero cells (Figure 6A and B, respectively).",
      "key": "6625a49ff9d9792ac1c4a9a56a192378",
      "line": 73,
      "relation": "association",
      "source": 3,
      "target": 4
    },
    {
      "annotations": {
        "CellLine": {
          "A549 cell": true
        },
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 (Figure 6C) compared to Vero cells (Figure 6B). ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types (Figure 6B and C).",
      "key": "cf0b7d92f54a1b3292703cef01cf70bb",
      "line": 83,
      "relation": "association",
      "source": 6,
      "target": 4
    },
    {
      "annotations": {
        "CellLine": {
          "A549 cell": true
        },
        "Custom_CellLine": {
          "Vero E6 cell": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 (Figure 6C) compared to Vero cells (Figure 6B). ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types (Figure 6B and C).",
      "key": "836e5bef29ab1f36ae860bcc171335a5",
      "line": 82,
      "relation": "decreases",
      "source": 1,
      "target": 6
    },
    {
      "annotations": {
        "Cell": {
          "monocyte": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "ATV/RTV and CQ were similarly efficient to inhibit viral replication in the human monocytes (Figure 7A).",
      "key": "69de24ab1f7ced678a13874faa3b75e1",
      "line": 92,
      "relation": "decreases",
      "source": 1,
      "target": 6
    },
    {
      "annotations": {
        "Concentration": {
          "10 μM": true
        },
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Moreover, we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant, which ranged from 20- to 60-fold depending on the cell donor (Figure 7C, open circles in nil-treated cells). The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 µM, ATV/RTV at both 1 and 10 µM and CQ at 10 µM (Figure 7C).",
      "key": "523b87c3fcba4cb56f708899a35feb4e",
      "line": 104,
      "relation": "decreases",
      "source": 1,
      "target": 12
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Moreover, we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant, which ranged from 20- to 60-fold depending on the cell donor (Figure 7C, open circles in nil-treated cells). The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 µM, ATV/RTV at both 1 and 10 µM and CQ at 10 µM (Figure 7C).",
      "key": "9fbfad6fc5c66960f9c425c17e6983c3",
      "line": 99,
      "relation": "positiveCorrelation",
      "source": 14,
      "target": 12
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Another biomarker of uncontrolled pro-inflammatory cytokine response, TNF-α, was up-regulated 40-fold during virus infection (Figure 7D). Only the combination of ATV/RTV could significantly prevent the induction of TNF-α release (Figure 7D).",
      "key": "b89e3259a4bbf1a9ea58cccc63e3b2a3",
      "line": 110,
      "relation": "positiveCorrelation",
      "source": 14,
      "target": 4
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Another biomarker of uncontrolled pro-inflammatory cytokine response, TNF-α, was up-regulated 40-fold during virus infection (Figure 7D). Only the combination of ATV/RTV could significantly prevent the induction of TNF-α release (Figure 7D).",
      "key": "8202e3286a6b3190e2813e18fbc1ee3c",
      "line": 111,
      "relation": "positiveCorrelation",
      "source": 14,
      "target": 13
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Moreover, we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant, which ranged from 20- to 60-fold depending on the cell donor (Figure 7C, open circles in nil-treated cells). The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 µM, ATV/RTV at both 1 and 10 µM and CQ at 10 µM (Figure 7C).",
      "key": "6cac8e92fd688783a446a3ca69e65ef3",
      "line": 99,
      "relation": "positiveCorrelation",
      "source": 12,
      "target": 14
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Preprint": true
        },
        "PublicationType": {
          "Research": true
        },
        "Section": {
          "Results": true
        }
      },
      "citation": {
        "db": "DOI",
        "db_id": "10.1101/2020.04.04.020925v2"
      },
      "evidence": "Another biomarker of uncontrolled pro-inflammatory cytokine response, TNF-α, was up-regulated 40-fold during virus infection (Figure 7D). Only the combination of ATV/RTV could significantly prevent the induction of TNF-α release (Figure 7D).",
      "key": "4591b03348f8cb4ecd21089f24e15da5",
      "line": 111,
      "relation": "positiveCorrelation",
      "source": 13,
      "target": 14
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:atazanavir)",
      "concept": {
        "name": "atazanavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "62e7c1c5acbe5d720e7750e3b7297d45"
    },
    {
      "bel": "a(CHEBI:chloroquine)",
      "concept": {
        "name": "chloroquine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "c368fe204031ce23a04cc402914492f6"
    },
    {
      "bel": "a(CHEBI:ritonavir)",
      "concept": {
        "name": "ritonavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "07c1651afef7019b0cb107f1ce5fef12"
    },
    {
      "bel": "a(GO:\"RNA viral genome\")",
      "concept": {
        "name": "RNA viral genome",
        "namespace": "GO"
      },
      "function": "Abundance",
      "id": "58886676a15d0caee20d11c6dbfcfc7d"
    },
    {
      "bel": "a(TAX:\"Severe acute respiratory syndrome coronavirus 2\")",
      "concept": {
        "name": "Severe acute respiratory syndrome coronavirus 2",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "c41851da59cc36c21b2e8acf24c1f46d"
    },
    {
      "bel": "bp(MESH:\"Hydrogen Bonding\")",
      "concept": {
        "name": "Hydrogen Bonding",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "0ce5afd7f0b6ebe292dc6d5a4de0ded1"
    },
    {
      "bel": "bp(MESH:\"Virus Replication\")",
      "concept": {
        "name": "Virus Replication",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "f511c0a55a7b8aa880279fba6181fd8c"
    },
    {
      "bel": "complex(a(CHEBI:atazanavir), p(COVID:ORF1ab, frag(\"3264_3569\")))",
      "function": "Complex",
      "id": "8feb8fb5f754b126ffc4f3ce53e36646",
      "members": [
        {
          "bel": "a(CHEBI:atazanavir)",
          "concept": {
            "name": "atazanavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "62e7c1c5acbe5d720e7750e3b7297d45"
        },
        {
          "bel": "p(COVID:ORF1ab, frag(\"3264_3569\"))",
          "concept": {
            "name": "ORF1ab",
            "namespace": "COVID"
          },
          "function": "Protein",
          "id": "8b1aed13f6853876f8b68f28deac1a26",
          "variants": [
            {
              "kind": "frag",
              "start": 3264,
              "stop": 3569
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:ritonavir), p(COVID:ORF1ab, frag(\"3264_3569\")))",
      "function": "Complex",
      "id": "84c7ea8032f9f8e86fcae2e7989f5a44",
      "members": [
        {
          "bel": "a(CHEBI:ritonavir)",
          "concept": {
            "name": "ritonavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "07c1651afef7019b0cb107f1ce5fef12"
        },
        {
          "bel": "p(COVID:ORF1ab, frag(\"3264_3569\"))",
          "concept": {
            "name": "ORF1ab",
            "namespace": "COVID"
          },
          "function": "Protein",
          "id": "8b1aed13f6853876f8b68f28deac1a26",
          "variants": [
            {
              "kind": "frag",
              "start": 3264,
              "stop": 3569
            }
          ]
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:atazanavir), a(CHEBI:ritonavir))",
      "function": "Composite",
      "id": "bb16152ee7077d33f42d6c505f557e69",
      "members": [
        {
          "bel": "a(CHEBI:atazanavir)",
          "concept": {
            "name": "atazanavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "62e7c1c5acbe5d720e7750e3b7297d45"
        },
        {
          "bel": "a(CHEBI:ritonavir)",
          "concept": {
            "name": "ritonavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "07c1651afef7019b0cb107f1ce5fef12"
        }
      ]
    },
    {
      "bel": "p(COVID:ORF1ab)",
      "concept": {
        "name": "ORF1ab",
        "namespace": "COVID"
      },
      "function": "Protein",
      "id": "3e2ae75f3061012cb65ea6b97f7db096"
    },
    {
      "bel": "p(COVID:ORF1ab, frag(\"3264_3569\"))",
      "concept": {
        "name": "ORF1ab",
        "namespace": "COVID"
      },
      "function": "Protein",
      "id": "8b1aed13f6853876f8b68f28deac1a26",
      "variants": [
        {
          "kind": "frag",
          "start": 3264,
          "stop": 3569
        }
      ]
    },
    {
      "bel": "p(HGNC:IL6)",
      "concept": {
        "name": "IL6",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8a1d3c4828c5416eba867c395cc65caa"
    },
    {
      "bel": "p(HGNC:TNF)",
      "concept": {
        "name": "TNF",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "fdc1c1f5a73c3c992b6eb71ce9b6908e"
    },
    {
      "bel": "path(DO:\"COVID-19\")",
      "concept": {
        "name": "COVID-19",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "6f9f1c2e8012537e503a758c6bfaff0f"
    }
  ]
}